Aura Biosciences Files 2025 Proxy Statement

TL;DR

Aura Biosciences just dropped its proxy statement for the 2025 meeting. Get ready to vote.

AI Summary

Aura Biosciences, Inc. filed its definitive proxy statement (DEF 14A) on April 24, 2025, for its fiscal year ending December 31, 2024. The filing pertains to the company's annual meeting and related corporate governance matters. The company is based in Boston, MA, and operates in the biological products sector.

Why It Matters

This filing provides shareholders with essential information regarding the company's governance, executive compensation, and voting matters for the upcoming annual meeting.

Risk Assessment

Risk Level: low — This is a routine DEF 14A filing, which is standard for publicly traded companies and does not inherently indicate new risks.

Key Players & Entities

• Aura Biosciences, Inc. (company) — Registrant
• 0000950170-25-058062 (filing_id) — Accession Number
• 20250424 (date) — Filing Date
• 20250617 (date) — Period of Report
• 80 GUEST STREET, BOSTON, MA 02135 (address) — Business and Mail Address

FAQ

From the Filing

0000950170-25-058062.txt : 20250424 0000950170-25-058062.hdr.sgml : 20250424 20250424161514 ACCESSION NUMBER: 0000950170-25-058062 CONFORMED SUBMISSION TYPE: DEF 14A PUBLIC DOCUMENT COUNT: 19 CONFORMED PERIOD OF REPORT: 20250617 FILED AS OF DATE: 20250424 DATE AS OF CHANGE: 20250424 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aura Biosciences, Inc. CENTRAL INDEX KEY: 0001501796 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 320271970 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEF 14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-40971 FILM NUMBER: 25867511 BUSINESS ADDRESS: STREET 1: 80 GUEST STREET CITY: BOSTON STATE: MA ZIP: 02135 BUSINESS PHONE: (617)500-8864 MAIL ADDRESS: STREET 1: 80 GUEST STREET CITY: BOSTON STATE: MA ZIP: 02135 DEF 14A 1 aura-20250424.htm DEF 14A DEF 14A false 0001501796 DEF 14A 0001501796 2024-01-01 2024-12-31 Table of Contents   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box:   ☐   Preliminary Proxy Statement       ☐   Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))       ☒   Definitive Proxy Statement       ☐   Definitive Additional Materials       ☐   Soliciting Material under §240.14a-12   AURA BIOSCIENCES, INC. (Name of Registrant as Specified In Its Charter)   (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply):   ☒   No fee required       ☐   Fee paid previously with preliminary materials       ☐   Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11   Table of Contents AURA BIOSCIENCES, INC. 80 Guest Street Boston, MA 02135 NOTICE OF 2025 ANNUAL MEETING OF STOCKHOLDERS To be held June 17, 2025 Notice is hereby given that the 2025 Annual Meeting of Stockholders, or Annual Meeting, of Aura Biosciences, Inc., will be held online on June 17, 2025 at 9:30 a.m. Eastern Time. This year’s Annual Meeting will be held virtually. You may attend the meeting virtually via the Internet at www.virtualshareholdermeeting.com/AURA2025 where you will be able to vote electronically and submit questions. You will need the 16-digit control number included with the Notice of Internet Availability of Proxy Materials being mailed to you separately in order to attend the Annual Meeting. The purpose of the Annual Meeting is the following: 1. To elect two Class I directors to our Board of Directors, to serve until the 2028 annual meeting of stockholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal; 2. To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025; and 3. To transact any other business properly brought before the Annual Meeting or any adjournment or postponement of the Annual Meeting. The proposal for the election of directors relates solely to the election of two Class I directors nominated by the Board of Directors. Only Aura Biosciences, Inc. stockholders of record at the close of business on April 21, 2025, will be entitled to vote at the Annual Meeting and any adjournment or postponement thereof. Aura Biosciences, Inc. is following the Securities and Exchange Commission’s “Notice and Access” rule that allows companies to furnish their proxy materials by posting them on the Internet. As a result, we are mailing to our stockholde